Lung neuroendocrine tumors

Neuroendocrine tumors are a large and heterogeneous group of tumors that develop from neuroendocrine cells. To define this type of tumor, the well-established term “carcinoid” continues to be used in clinical practice for years. In accordance with the characteristics of embryogenesis, three groups of neuroendocrine tumors are distinguished. The source of these tumors are neuroendocrine cells, which are located in almost all organs. The term itself and the concept of “neuroendocrine cell” have historically been repeatedly reassessed. In 1969 A. Pearse, based on the ability of these cells to utilize and decarboxylate amine precursors, introduced the term “APUD system” (aminoprecursor uptake and decarboxylation). Neuroendocrine cells, although they can secrete the same substances as neurons, but, unlike the latter, they participate not in topical, but in paracrine regulation of organs and tissues. They are located in all human organs and are the most important tool for maintaining homeostasis.

In recent years, more and more publications have appeared about the frequent localization of neuroendocrine tumors in the lungs, and new approaches to the diagnosis of this pathology. This review presents the diagnostic features and clinical course of pulmonary neuroendocrine tumors.

1. Imyanitov E.N. Epidemiology and biology of neuroendocrine tumors. Prakticheskaya oncologiya = Practical Oncology 2005;6(4): 202–5. (In Russ.).

2. Pearse A.G. The cytochemistry and ultrastructure of polypeptide hormone-producing cells of the APUD series and the embryologic, physiologic and pathologic implications of the concept. J Histochem Cytochem 1969;17(5):303–13. DOI: 10.1177/17.5.303

3. Kim M., Mun H., Sung C.O. et al. Patient-derived lung cancer organoids as in vitro cancer models for therapeutic screening. Nat Commun 2019;10(1):3991. DOI: 10.1038/s41467-019-11867-6

4. Lei Y., Feng H., Qiang H. et al. Clinical characteristics and prognostic factors of surgically resected combined small cell lung cancer: a retrospective study. Lung Cancer 2020;146:244–51. DOI: 10.1016/j.lungcan.2020.06.021

5. WHO Classification of Tumours Editorial Board. Endocrine and neuroendocrine tumours. WHO classification of tumours series. 5th edn. Vol. 8. Lyon (France): IARC, 2022.

6. WHO Classification of Tumours Editorial Board. Thoracic tumours. WHO classification of tumours series. 5th edn. Vol. 5. Lyon (France): IARC, 2021.

7. Gurevich L.E., Voronkova I.A., Marova E.I. et al. Clinical and morphological characteristic of ACTH producing tumors of various localization and the ectopic Cushing’s syndrome. Almanakh klinicheskoy meditsiny = Almanac of Clinical Medicine 2017;45(4):289–301. (In Russ.). DOI: 10.18786/2072-0505-2017-45-4-289-301

8. Volkova N.I., Porksheyan M.I. Diagnosis of neuroendocrine tumors: the role of the therapist. Consilium Medicum 2016;18(4):44–8. (In Russ.).

9. Barakat M.T., Meeran K., Bloom S.R. Neuroendocrine tumours. Endocr Related Cancer 2004;11(1):1–18. DOI: 10.1677/erc.0.0110001

10. Alekseeva T.R., Beltsevich D.G., Bokhyan V.Yu. et al. Neuroendocrine tumors. General principles of diagnosis and treatment. A practical guide. Ed. by V.A. Gorbunova. Moscow: GЕОTAR-Media, 2021. 600 p.

11. Rudin C.M., Brambilla E., Faivre-Finn C., Sage J. Small-cell lung cancer. Nat Rev Dis Prim 2021;7(1):3. DOI: 10.1038/s41572-020-00235-0

12. Gut P., Komarowska H., Czarnywojtek A. et al. Familial syndromes associated with neuroendocrine tumours. Contemp Oncol (Pozn) 2015;19(3):176–83. DOI: 10.5114/wo.2015.52710

13. Stelwagen J., de Vries E.G.E., Walenkamp A.M.E. Current treatment strategies and future directions for extrapulmonary neuroendocrine carcinomas: a review. JAMA Oncol 2021;7(5):759–70.

14. Modlin I.M., Oberg K., Chung D.C. et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol 2008;9(1):61–72. DOI: 10.1016/S1470-2045(07)70410-2

15. Imyanitov E.N., Kuligina E.Sh., Belogubova E.V. et al. Mechanisms of lung cancer. Drug Discov Today: Dis Mech 2005;2:213–23. DOI: 10.1016/j.ddmec.2005.05.015

16. Robelin P., Hadoux J., Forestier J. et al. Characterization, prognosis, and treatment of patients with metastatic lung carcinoid tumors. J Thorac Oncol 2019;14(6):993–1002. DOI: 10.1016/j.jtho.2019.02.002

17. Rubino M., Scoazec J.Y., Pisa E. et al. Lung carcinoids with high proliferative activity: further support for the identification of a new tumor category in the classification of lung neuroendocrine neoplasms. Lung Cancer 2020;148:149–58. DOI: 10.1016/j.lungcan.2020.08.001

18. Gorbunova V.A. Neuroendocrine tumors. General principles of diagnostics and treatment. Moscow: Kodeks, 2015. 456 p.

19. Murray N., Salgia R., Fossella F.V. Targeted molecules in small cell lung cancer. Semin Oncol 2004;31(Suppl 1):106–11. DOI: 10.1053/j.seminoncol.2003.12.021

20. Kulke M.H. Neuroendocrine tumours: clinical presentation and management of localized disease. Cancer Treat Rev 2003;29(5):363–70. DOI: 10.1016/s0305-7372(03)00072-0

21. Sattler M., Salgia R. Molecular and cellular biology of small cell lung cancer. Semin Oncol 2003;30(1):57–71. DOI: 10.1053/sonc.2003.50019

22. Gurevich L.E., Korsakova N.A., Voronkova I.A. et al. Immunohistochemical determination of the expression of somatostatin receptors of types 1, 2a, 3 and 5 in neuroendocrine tumors of various localization and degree of malignancy. Almanakh klinicheskoy medirsiny = Almanac of Clinical Medicine 2016;44(4):378–90. (In Russ.).

23. Miyanaga A., Masuda M., Motoi N. et al. Whole-exome and RNA sequencing of pulmonary carcinoid reveals chromosomal rearrangements associated with recurrence. Lung Cancer 2020;145:85–94. DOI: 10.1016/j.lungcan.2020.03.027

24. Chan J.M., Quintanal-Villalonga Á., Gao V.R. et al. Signatures of plasticity, metastasis, and immunosuppression in an atlas of human small cell lung cancer. Cancer Cell 2021;39(11):1479–96. e18. DOI: 10.1016/j.ccell.2021.09.008

25. Cree I.A., Tan P.H., Travis W.D. et al. Counting mitoses: SI(ze) matters! Мod Pathol 2021;34(9):1651–7. DOI: 10.1038/s41379-021-00825-7

26. Dermawan J.K., Farver C.F. The Prognostic significance of the 8th edition TNM staging of pulmonary carcinoid tumors: a single institution study with long-term follow-up. Am J Surg Pathol 2019;43(9):1291–6. DOI: 10.1097/PAS.0000000000001268

27. Dermawan J.K.T., Farver C.F. The role of histologic grading and Ki-67 index in predicting outcomes in pulmonary carcinoid tumors. Am J Surg Pathol 2020;44(2):224–31. DOI: 10.1097/PAS.0000000000001358

28. Ferolla P., Berruti A., Spada F. et al. Efficacy and safety of lanreotide autogel and temozolomide combination therapy in progressive thoracic neuroendocrine tumors (carcinoid): results from the phase 2 ATLANT study. Neuroendocrinology 2023;113(3):332–42. doi: 10.1159/000526811

29. Franchina T., Proto C., Russo A. et al. Treatment options for small cell lung cancer: does lanreotide represent a new choice? Lung Cancer 2013;80(Suppl 1):S20–1. Available at: https://ur.booksc.me/ book/24770121/24162c (accessed: 14.10.2022).

30. Hermans B.C.M., Derks J.L., Moonen L. et al. Pulmonary neuroendocrine neoplasms with well differentiated morphology and high proliferative activity: illustrated by a case series and review of the literature. Lung Cancer 2020;150:152–8. DOI: 10.1016/j.lungcan.2020.10.015

31. Anlauf M. Neuroendocrine neoplasms of the gastroenteropancreatic system: pathology and classification. Horm Metab Res 2011;43(12): 825–31. DOI: 10.1055/s-0031-1291307

32. Volante M., Brizzi M.P., Faggiano A. et al. Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: a proposal of scoring system correlated with somatostatin receptor scintigraphy. Mod Pathol 2007;20(11):1172–82. DOI: 10.1038/modpathol.3800954

33. Emelyanova G.S., Kuzminov A.E., Orel N.F. et al. Lanreotide for the treatment of patients with disseminated high-grade neuroendocrine tumors: the experience of Lanreotide application in case of unsatisfactory tolerability of octreotide. Sovremennaya oncologiya = Journal of Modern Oncology 2016;18(1):80–3. (In Russ.).

34. Barbieri F., Albertelli M., Grillo F. et al. Neuroendocrine tumors: insights into innovative therapeutic options and rational development of targeted therapies. Drug Discov Today 2014;19(4):458–68. DOI: 10.1016/j.drudis.2013.10.015